|
|
|
|
LEADER |
01791 am a22002053u 4500 |
001 |
132610 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Facklam, Amanda L.
|e author
|
100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
700 |
1 |
0 |
|a Volpatti, Lisa R
|e author
|
700 |
1 |
0 |
|a Anderson, Daniel Griffith
|e author
|
245 |
0 |
0 |
|a Biomaterials for Personalized Cell Therapy
|
260 |
|
|
|b Wiley,
|c 2021-09-21T15:05:54Z.
|
856 |
|
|
|z Get fulltext
|u https://hdl.handle.net/1721.1/132610
|
520 |
|
|
|a Cell therapy has already had an important impact on healthcare and provided new treatments for previously intractable diseases. Notable examples include mesenchymal stem cells for tissue regeneration, islet transplantation for diabetes treatment, and T cell delivery for cancer immunotherapy. Biomaterials have the potential to extend the therapeutic impact of cell therapies by serving as carriers that provide 3D organization and support cell viability and function. With the growing emphasis on personalized medicine, cell therapies hold great potential for their ability to sense and respond to the biology of an individual patient. These therapies can be further personalized through the use of patient-specific cells or with precision biomaterials to guide cellular activity in response to the needs of each patient. Here, the role of biomaterials for applications in tissue regeneration, therapeutic protein delivery, and cancer immunotherapy is reviewed, with a focus on progress in engineering material properties and functionalities for personalized cell therapies.
|
520 |
|
|
|a Juvenile Diabetes Research Foundation (Grant 2-SRA-2019-714-S-B)
|
520 |
|
|
|a Leona M. and Harry B. Helmsley Charitable Trust (Grant 2017PG-T1D027)
|
546 |
|
|
|a en
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Advanced Materials
|